LI-RADS: A case-based review of the new categorization of liver findings in patients with end-stage liver disease

Radiographics

Volumn 32, Issue 7, 2012, Pages 1977-1995

  Purysko, Andrei S ^a   Remer, Erick M ^a   Coppa, Christopher P ^a   Leão Filho, Hilton M ^b   Thupili, Chakradhar R ^a   Veniero, Joseph C ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b HCor   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DIAGNOSTIC IMAGING; END STAGE LIVER DISEASE; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; PRACTICE GUIDELINE; RADIOLOGY; STANDARD; UNITED STATES;

CARCINOMA, HEPATOCELLULAR; DIAGNOSTIC IMAGING; END STAGE LIVER DISEASE; HUMANS; LIVER NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; RADIOLOGY; UNITED STATES;

EID: 84869214815     PISSN: 02715333     EISSN: 15271323     Source Type: Journal    
DOI: 10.1148/rg.327125026     Document Type: Article

References (49)

1. International Agency for Research on Cancer, World Health Organization (WHO). GLOBOCAN 2008: cancer incidence, mortality and prevalence worldwide in 2008. Available at: http://globocan.iarc.fr. Accessed April 19, 2012.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55(2): 74-108.
3. London WT, McGlynn KA. Liver cancer. In: Schottenfeld D, Fraumeni JF Jr, eds. Cancer epidemiology and prevention. 3rd ed. New York, NY: Oxford University Press, 2006; 763-786.
4. Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 2010;15(suppl 4):5-13.
5. Center MM, Jemal A. International trends in liver cancer incidence rates. Cancer Epidemiol Biomarkers Prev 2011;20(11):2362-2368.
6. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362(9399):1907-1917.
7. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009;27(9):1485-1491.
8. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference- European Association for the Study of the Liver. J Hepatol 2001;35(3):421-430.
9. Sharma P, Saini SD, Kuhn LB, et al. Knowledge of hepatocellular carcinoma screening guidelines and clinical practices among gastroenterologists. Dig Dis Sci 2011;56(2):569-577.
10. Thompson Coon J, Rogers G, Hewson P, et al. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis. Health Technol Assess 2007;11(34):1-206.
11. Becker-Weidman DJ, Kalb B, Sharma P, et al. Hepatocellular carcinoma lesion characterization: single-institution clinical performance review of multiphase gadolinium-enhanced MR imaging-comparison to prior same-center results after MR systems improvements. Radiology 2011;261(3):824-833.
12. Lee KH, O'Malley ME, Haider MA, Hanbidge A. Triple-phase MDCT of hepatocellular carcinoma. AJR Am J Roentgenol 2004;182(3):643-649.
13. Sharma P, Kalb B, Kitajima HD, et al. Optimization of single injection liver arterial phase gadolinium enhanced MRI using bolus track real-time imaging. J Magn Reson Imaging 2011;33(1):110-118.
14. Altekruse SF, McGlynn KA, Dickie LA, Kleiner DE. Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992-2008. Hepatology 2012;55(2):476-482.
15. Radiological Society of North America Informatics. Radiology report initiative. Available at: http://www.rsna.org/Reporting_Initiative.aspx. Accessed April 19, 2012.
16. Reiner BI. Medical imaging data reconciliation. 4. Reconciliation of radiology reports and clinical outcomes data. J Am Coll Radiol 2011;8(12):858-862.
17. Krinsky G. Terminology of hepatocellular nodules in cirrhosis: plea for consistency. Radiology 2002; 224(3):638.
18. Lee JM, Trevisani F, Vilgrain V, Wald C. Imaging diagnosis and staging of hepatocellular carcinoma. Liver Transpl 2011;17(suppl 2):S34-S43.
19. Radiological Society of North America. LI-RADS enables standardized interpretation, reporting of HCC. RSNA News 2012;22(2):13-14.
20. Napel SA, Beaulieu CF, Rodriguez C, et al. Automated retrieval of CT images of liver lesions on the basis of image similarity: method and preliminary results. Radiology 2010;256(1):243-252.
21. Schwartz LH, Panicek DM, Berk AR, Li Y, Hricak H. Improving communication of diagnostic radiology findings through structured reporting. Radiology 2011;260(1):174-181.
22. American College of Radiology. Quality and safety resources: Liver Imaging-Reporting and Data System. Available at: http://www.acr.org/Quality-Safety/Resources/LIRADS. Accessed April 22, 2012.
23. Dixon AK. The impact of medical imaging on the physician's diagnostic and therapeutic thinking. Eur Radiol 1998;8(3):488-490.
24. Hecht EM, Holland AE, Israel GM, et al. Hepatocellular carcinoma in the cirrhotic liver: gadolinium-enhanced 3D T1-weighted MR imaging as a stand-alone sequence for diagnosis. Radiology 2006;239(2):438-447.
25. Willatt JM, Hussain HK, Adusumilli S, Marrero JA. MR imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology 2008;247(2):311-330.
26. Ayuso C, Rimola J, García-Criado A. Imaging of HCC. Abdom Imaging 2012;37(2):215-230.
27. Efremidis SC, Hytiroglou P. The multistep process of hepatocarcinogenesis in cirrhosis with imaging correlation. Eur Radiol 2002;12(4):753-764.
28. Marrero JA, Hussain HK, Nghiem HV, Umar R, Fontana RJ, Lok AS. Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transpl 2005;11(3):281-289.
29. Sherman M. The radiological diagnosis of hepatocellular carcinoma. Am J Gastroenterol 2010;105 (3):610-612.
30. Fowler KJ, Brown JJ, Narra VR. Magnetic resonance imaging of focal liver lesions: approach to imaging diagnosis. Hepatology 2011;54(6):2227-2237.
31. Jeong YY, Mitchell DG, Kamishima T. Small (<20 mm) enhancing hepatic nodules seen on arterial phase MR imaging of the cirrhotic liver: clinical implications. AJR Am J Roentgenol 2002;178(6): 1327-1334.
32. Khalili K, Kim TK, Jang HJ, Yazdi LK, Guindi M, Sherman M. Indeterminate 1-2-cm nodules found on hepatocellular carcinoma surveillance: biopsy for all, some, or none? Hepatology 2011;54 (6):2048-2054.
33. Hwang SH, Yu JS, Kim KW, Kim JH, Chung JJ. Small hypervascular enhancing lesions on arterial phase images of multiphase dynamic computed tomography in cirrhotic liver: fate and implications. J Comput Assist Tomogr 2008;32(1):39-45.
34. Sakata J, Shirai Y, Wakai T, Kaneko K, Nagahashi M, Hatakeyama K. Preoperative predictors of vascular invasion in hepatocellular carcinoma. Eur J Surg Oncol 2008;34(8):900-905.
35. Ueda K, Matsui O, Kawamori Y, et al. Hypervascular hepatocellular carcinoma: evaluation of hemodynamics with dynamic CT during hepatic arteriography. Radiology 1998;206(1):161-166.
36. Dodd GD 3rd, Memel DS, Baron RL, Eichner L, Santiguida LA. Portal vein thrombosis in patients with cirrhosis: does sonographic detection of intrathrombus flow allow differentiation of benign and malignant thrombus? AJR Am J Roentgenol 1995;165(3):573-577.
37. Leoni S, Piscaglia F, Golfieri R, et al. The impact of vascular and nonvascular findings on the noninvasive diagnosis of small hepatocellular carcinoma based on the EASL and AASLD criteria. Am J Gastroenterol 2010;105(3):599-609.
38. Burrel M, Llovet JM, Ayuso C, et al. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology 2003;38(4):1034-1042.
39. Khalili K, Kim TK, Jang HJ, et al. Optimization of imaging diagnosis of 1-2 cm hepatocellular carcinoma: an analysis of diagnostic performance and resource utilization. J Hepatol 2011;54(4):723-728.
40. Hussain SM, Reinhold C, Mitchell DG. Cirrhosis and lesion characterization at MR imaging. RadioGraphics 2009;29(6):1637-1652.
41. Varela M, Sanchez W, Bruix J, Gores GJ. Hepatocellular carcinoma in the setting of liver transplantation. Liver Transpl 2006;12(7):1028-1036.
42. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011;53 (3):1020-1022.
43. Brancatelli G, Baron RL, Peterson MS, Marsh W. Helical CT screening for hepatocellular carcinoma in patients with cirrhosis: frequency and causes of false-positive interpretation. AJR Am J Roentgenol 2003;180(4):1007-1014.
44. Yu JS, Kim KW, Jeong MG, Lee JT, Yoo HS. Nontumorous hepatic arterial-portal venous shunts: MR imaging findings. Radiology 2000;217(3):750-756.
45. Holland AE, Hecht EM, Hahn WY, et al. Importance of small (< or = 20-mm) enhancing lesions seen only during the hepatic arterial phase at MR imaging of the cirrhotic liver: evaluation and comparison with whole explanted liver. Radiology 2005;237(3):938-944.
46. Colagrande S, Centi N, Galdiero R, Ragozzino A. Transient hepatic intensity differences. 1. Those associated with focal lesions. AJR Am J Roentgenol 2007;188(1):154-159.
47. OPTN policy management. Available at: http://optn.transplant.hrsa.gov/policiesAndBylaws/policies.asp. Accessed April 22, 2012.
48. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334(11):693-699.
49. OPTN/UNOS Liver and Intestinal Organ Transplantation Committee. Report to the Board of Directors. Available at: http://optn.transplant.hrsa.gov/CommitteeReports/board_main_Liver&IntestinalOrganTransplantationCommittee_11_17_2011_17_35.pdf. Accessed April 22, 2012.